Clinical Research Directory
Browse clinical research sites, groups, and studies.
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Sponsor: Pfizer
Summary
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better. Participants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.
Official title: A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
550
Start Date
2025-12-09
Completion Date
2034-03-11
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
PF-08634404
Concentrate for solution for infusion
Atezolizumab
Injection for intravenous use
Chemotherapy
Injection for intravenous use
Locations (26)
Highlands Oncology Group
Fayetteville, Arkansas, United States
Highlands Oncology Group
Rogers, Arkansas, United States
Highlands Oncology Group
Springdale, Arkansas, United States
BRCR Coral Springs
Coral Springs, Florida, United States
BRCR Global - Coral Springs
Coral Springs, Florida, United States
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States
BRCR Global - Tamarac
Tamarac, Florida, United States
Texas Oncology - Gulf Coast
Beaumont, Texas, United States
Texas Oncology - San Antonio
Fredericksburg, Texas, United States
Texas Oncology - Gulf Coast
Houston, Texas, United States
Texas Oncology - Gulf Coast
Houston, Texas, United States
Texas Oncology - San Antonio
New Braunfels, Texas, United States
Texas Oncology - Gulf Coast
Pearland, Texas, United States
Texas Oncology - San Antonio
San Antonio, Texas, United States
Texas Oncology - San Antonio
San Antonio, Texas, United States
Texas Oncology - San Antonio
San Antonio, Texas, United States
Texas Oncology - Gulf Coast
Sugar Land, Texas, United States
Texas Oncology - Gulf Coast
The Woodlands, Texas, United States
Texas Oncology - Gulf Coast
Webster, Texas, United States
Border Medical Oncology Research Unit
Albury, New South Wales, Australia
Kansai Medical University Hospital
Hirakata, Osaka, Japan
Doctor's Center Hematology & Oncology Group
Manatí, Puerto Rico
Pan American Center for Oncology Trials, LLC - Mayaguez Office Mayaguez Medical Center
Mayagüez, Puerto Rico
Pan American Center for Oncology Trials, LLC
San Juan, Puerto Rico
Hospital Oncologico Dr. Isaac Gonzalez-Martinez
San Juan, Puerto Rico
Taipei Medical University Hospital
Taipei, Taiwan